A first-order welcome

25% OFF

A little more for your first order.

First orders of eligible single-vial products. Bulk kits and mixed carts excluded.

Copy now. Enter it yourself at checkout.

Shop single vials
Offer details

25% off your first eligible single-vial order total, including standard shipping. One use per customer email. Bulk kits and any cart containing a kit are excluded. The discount is calculated from current listed prices, including eligible sale prices.

0 items in cart

Your privacy choices. Essential storage keeps your cart and checkout working. Choose whether to allow optional analytics, performance, and advertising measurement tools.

Privacy controls

Your Privacy Choices

Essential storage keeps your cart and checkout working. You can separately control optional analytics and opt out of disclosures that may be considered sale or sharing for advertising.

Sale or sharing for advertising

No sale/sharing opt-out is currently saved for this browser.

Optional site tools

With permission, analytics, performance, and advertising measurement tools help us understand site use. Advertising measurement may include page visits and, after a paid order, purchase value, currency, item identifiers, item prices, and quantities. It remains off whenever an opt-out is active.

Read the Privacy Policy for details.

Eloralintide Research4 min readUpdated

Published by Pept Research LLC. Send a documentation question or correction.

Eloralintide Research Timeline: Discovery to Phase 3

A dated guide to the main Eloralintide evidence sources and how to interpret development stages without confusing them with product approval.

The Eloralintide research timeline includes receptor investigation, published early clinical studies, and the Phase 3 ENLIGHTEN program. Research status checked October 31, 2026. Development information can change, so use the linked primary sources when checking a later update.

This timeline summarizes evidence types and study milestones. It does not provide clinical-use instructions or transfer clinical findings to independently supplied research materials.

Eloralintide research milestones at a glance

Evidence stageSource to reviewDate and scope of the record
Discovery and receptor investigationDiscovery publication, PMID 41109426Published online October 16, 2025; experimental background for the compound
Phase 1Proof-of-concept study, PMID 41559929Published online January 20, 2026; the separate 12-week study
Phase 2Randomized trial, PMID 41207310Published online November 6, 2025; the 48-week study
Phase 3ENLIGHTEN-1 registry record, NCT07321886Last update posted September 22, 2026; recruiting, with no results posted when checked

These entries are a reading map, not a claim that every study in the development program is listed here.

The table is ordered by evidence stage, not publication date. The 12-week Phase 1 report appeared after the Phase 2 publication; this does not reverse the sequence of the underlying experiments.

Discovery research: establish the experimental context

Begin by identifying the study material and the questions investigated. The discovery paper is the appropriate starting point for understanding why later researchers examined the molecule. For the receptor vocabulary behind this work, see Eloralintide mechanism and amylin receptors.

Keep publication dates separate from experiment dates. A paper may describe work performed years earlier, and a later publication date does not necessarily indicate a later stage of experimentation.

Phase 1: read the design before the headline

The published Phase 1 report describes a 12-week, randomized, placebo-controlled study examining safety, tolerability, pharmacokinetics, and pharmacodynamics. Its observations concern that study population and protocol.

When reviewing an early study, record the participant population, duration, comparison groups, and measured endpoints. Check which conclusions are directly supported and which are proposals for further investigation. Do not convert the study's methods into instructions for a commercial RUO product.

Phase 2: a different study, a separate evidence record

The 48-week Phase 2 publication reports a randomized, double-blind, placebo-controlled investigation enrolling 263 participants at 46 US research centers.

Retain the paper as a separate record from the Phase 1 report. Different populations, follow-up periods, and methods mean that a simple side-by-side headline comparison can miss important context. In a literature summary, clearly label whether a statement comes from the abstract, full results, or supplementary methods.

Phase 3: the ENLIGHTEN program

Lilly's ENLIGHTEN-1 listing identifies a Phase III study of Eloralintide in adults with obesity or overweight without type 2 diabetes. The registry identifier shown is NCT07321886.

The registry records an actual study start of February 6, 2026, and estimated completion in July 2030. These are different fields: the estimated completion date is a plan, not a completed event or a results publication. Use the dated registry record when reconciling a sponsor page's broader date range.

A trial listing describes a study; it should not be presented as a completed results paper. Check the phase, status, record update, and any results posting separately. Phase 3 development also should not be described as regulatory approval.

Keep each study in a separate evidence record

A milestone belongs to the study described by its source. Preserve the compound identity, study identifier, evidence type, and review date for each entry. Our Eloralintide research records guide explains source traceability and the distinction between literature records and material documentation.

For an ongoing research tracker, use separate columns for publications, registry updates, and sponsor announcements. Label planned and completed milestones explicitly so that an anticipated event remains identifiable as a plan.

A repeatable way to check future updates

  1. Open the original publication, registry, or sponsor release.
  2. Record its identifier and the date you checked it.
  3. Distinguish actual events from planned milestones.
  4. Note whether methods and results are available.
  5. Preserve previous entries when making a dated correction.

For the compound introduction, return to what Eloralintide is. For material-specific questions, consult the Eloralintide product listing and laboratory evaluation guide; neither substitutes for a pharmaceutical clinical-trial record.

For laboratory research use only. Not for human or animal consumption or administration.

Research use only · Legal disclaimer

All Pept products labeled Research Use Only (RUO) are supplied strictly for lawful laboratory, analytical, and scientific research. They are not approved by the FDA for human or veterinary use and are not intended for clinical, diagnostic, cosmetic, or therapeutic applications.

By purchasing or handling RUO materials, you represent that they will be used only in an appropriate research environment by qualified personnel who understand the hazards, limitations, and regulatory requirements associated with experimental compounds. Products must never be administered to humans or animals.

You accept responsibility for lawful purchase, storage, handling, research, and disposal. Pept makes no representation that any product is safe or effective for a medical purpose and is not responsible for unauthorized use or handling outside the product documentation and applicable law.

Research purchasing

Frequently asked questions.

Where can I buy peptides online for laboratory research?

Pept Research offers an online catalog of research-use-only compounds for qualified laboratory purchasers. Browse our catalog to review available products, quantities, pricing, and supporting documentation.

What does research use only (RUO) mean?

Research use only means a material is supplied exclusively for qualified laboratory, analytical, or in-vitro research. Pept Research products are not for human or animal use or consumption, including self-experimentation. Review our Research Use Disclaimer for the complete restrictions.

Who can purchase from Pept Research?

Purchasers must be at least 21 years old and qualified to purchase and handle the requested research materials. Anyone purchasing for a laboratory, university, or business must have authority to act for that organization. Orders may require additional information or review under our Terms of Service.

Where can I find a Certificate of Analysis (COA)?

Visit our COA library to review available analytical reports. Match the compound, listed quantity, and lot information to the material you are evaluating. Reports describe the tested samples and measurements; they do not establish characteristics that were not tested. Contact us if you need help locating applicable documentation.

What are your shipping rates and delivery options?

Standard shipping is $9.99 for merchandise subtotals below $200. Orders with merchandise subtotals of $200 or more qualify for free shipping. Eligible orders use 2-Day Shipping where available. Carrier transit begins after package acceptance and does not include processing or order-review time. Available services and eligible destinations appear at checkout. See our Shipping Policy for details.

About this article

Is a registered study the same as published results?

No. A registry can describe the planned study and its status before results are available. Treat the design record and the results report as separate sources.

Do later development stages change RUO product restrictions?

No. A commercial material's intended-use restrictions and documentation remain separate from pharmaceutical development milestones.